TipRanks
Boston Scientific (BSX)
NYSE:BSX
US Market
Want to see BSX full AI Analyst Report?

Boston Scientific (BSX) Stock Forecast & Price Target

4,770 Followers
See the Price Targets and Ratings of:

BSX Analyst Ratings

Strong Buy
23Ratings
Strong Buy
19 Buy
4 Hold
0 Sell
Based on 23 analysts giving stock ratings to
Boston
Scientific
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

BSX Stock 12 Month Forecast

Average Price Target

$57.14
▲(14.59% Upside)
Based on 23 Wall Street analysts offering 12 month price targets for Boston Scientific in the last 3 months. The average price target is $57.14 with a high forecast of $70.00 and a low forecast of $48.00. The average price target represents a 14.59% change from the last price of $49.86.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"42":"$42","57":"$57","72":"$72","87":"$87","102":"$102"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":70,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$70.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":57.13636363636363,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$57.14</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":48,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$48.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[42,57,72,87,102],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,43.23,45.28923076923077,47.348461538461535,49.40769230769231,51.466923076923074,53.526153846153846,55.58538461538461,57.644615384615385,59.70384615384616,61.76307692307692,63.82230769230769,65.88153846153847,67.94076923076923,{"y":70,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,43.23,44.299720279720276,45.369440559440555,46.439160839160834,47.50888111888111,48.57860139860139,49.64832167832167,50.71804195804195,51.78776223776224,52.85748251748251,53.927202797202796,54.996923076923075,56.066643356643354,{"y":57.13636363636363,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,43.23,43.596923076923076,43.96384615384615,44.33076923076923,44.69769230769231,45.06461538461538,45.43153846153846,45.79846153846154,46.16538461538462,46.53230769230769,46.89923076923077,47.26615384615385,47.63307692307692,{"y":48,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":95.85,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 60,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":100.72,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 61,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":101.01,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":95.35,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":91.87,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 66,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.22,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 86,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 97,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.5,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 88,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.98,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 70,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.06,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 65,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.73,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.08,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.23,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$70.00Average Price Target$57.14Lowest Price Target$48.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Truist Financial Analyst forecast on BSX
Truist Financial
Truist Financial
$57→$51
Buy
2.29%
Upside
Reiterated
10/14/26
Analysts Offer Insights on Healthcare Companies: Boston Scientific (NYSE: BSX) and Ionis Pharmaceuticals (NASDAQ: IONS)
Piper Sandler Analyst forecast on BSX
Piper Sandler
Piper Sandler
$60
Buy
20.34%
Upside
Reiterated
10/14/26
Analysts Offer Insights on Healthcare Companies: Tectonic Therapeutic (NASDAQ: TECX), Boston Scientific (NYSE: BSX) and Liquidia Technologies (NASDAQ: LQDA)
Mizuho Securities Analyst forecast on BSX
Mizuho Securities
Mizuho Securities
$60→$55
Buy
10.31%
Upside
Assigned
10/13/26
Boston Scientific price target lowered to $55 from $60 at MizuhoBoston Scientific price target lowered to $55 from $60 at Mizuho
Leerink Partners Analyst forecast on BSX
Leerink Partners
Leerink Partners
$60→$55
Buy
10.31%
Upside
Assigned
10/12/26
Leerink Partners Sticks to Their Buy Rating for Boston Scientific (BSX)
BTIG
$56
Buy
12.31%
Upside
Reiterated
10/12/26
BTIG Sticks to Their Buy Rating for Boston Scientific (BSX)
Barclays
$48
Hold
-3.73%
Downside
Initiated
10/07/26
Barclays Keeps Their Hold Rating on Boston Scientific (BSX)
Citi
$48
Hold
-3.73%
Downside
Assigned
10/05/26
Citi cuts Boston Scientific target, opens 'downside 90-day catalyst watch'Citi cuts Boston Scientific target, opens 'downside 90-day catalyst watch'
Bernstein Analyst forecast on BSX
Unknown Analyst
Bernstein
Not Ranked
Bernstein
$60→$54
Buy
8.30%
Upside
Assigned
10/02/26
Bernstein Keeps Their Buy Rating on Boston Scientific (BSX)
J.P. Morgan Analyst forecast on BSX
J.P. Morgan
J.P. Morgan
$56
Buy
12.31%
Upside
Reiterated
10/01/26
Analysts Offer Insights on Healthcare Companies: Boston Scientific (NYSE: BSX) and Artiva Biotherapeutics, Inc. (NASDAQ: ARTV)
RBC Capital Analyst forecast on BSX
RBC Capital
RBC Capital
$70
Buy
40.39%
Upside
Reiterated
10/01/26
Boston Scientific (BSX) Receives a Buy from RBC Capital
Wells Fargo Analyst forecast on BSX
Wells Fargo
Wells Fargo
$50→$48
Hold
-3.73%
Downside
Assigned
09/24/26
Boston Scientific price target lowered to $48 from $50 at Wells FargoBoston Scientific price target lowered to $48 from $50 at Wells Fargo
Oppenheimer Analyst forecast on BSX
Oppenheimer
Oppenheimer
$85→$65
Buy
30.37%
Upside
Assigned
09/21/26
Boston Scientific price target lowered to $65 from $85 at OppenheimerBoston Scientific price target lowered to $65 from $85 at Oppenheimer
Bank of America Securities Analyst forecast on BSX
Bank of America Securities
Bank of America Securities
$54
Buy
8.30%
Upside
Reiterated
09/20/26
Analysts Offer Insights on Healthcare Companies: Danaher (NYSE: DHR), Argenx Se (NASDAQ: ARGX) and Boston Scientific (NYSE: BSX)
TD Cowen
$56
Buy
12.31%
Upside
Reiterated
09/17/26
Analyst Maintains Buy on Boston Scientific, Viewing Cyberattack Impact as Short-Lived Despite Trimmed Near-Term Forecasts
Jefferies
$60
Buy
20.34%
Upside
Reiterated
09/11/26
Jefferies Sticks to Its Buy Rating for Boston Scientific (BSX)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Truist Financial Analyst forecast on BSX
Truist Financial
Truist Financial
$57→$51
Buy
2.29%
Upside
Reiterated
10/14/26
Analysts Offer Insights on Healthcare Companies: Boston Scientific (NYSE: BSX) and Ionis Pharmaceuticals (NASDAQ: IONS)
Piper Sandler Analyst forecast on BSX
Piper Sandler
Piper Sandler
$60
Buy
20.34%
Upside
Reiterated
10/14/26
Analysts Offer Insights on Healthcare Companies: Tectonic Therapeutic (NASDAQ: TECX), Boston Scientific (NYSE: BSX) and Liquidia Technologies (NASDAQ: LQDA)
Mizuho Securities Analyst forecast on BSX
Mizuho Securities
Mizuho Securities
$60→$55
Buy
10.31%
Upside
Assigned
10/13/26
Boston Scientific price target lowered to $55 from $60 at MizuhoBoston Scientific price target lowered to $55 from $60 at Mizuho
Leerink Partners Analyst forecast on BSX
Leerink Partners
Leerink Partners
$60→$55
Buy
10.31%
Upside
Assigned
10/12/26
Leerink Partners Sticks to Their Buy Rating for Boston Scientific (BSX)
BTIG
$56
Buy
12.31%
Upside
Reiterated
10/12/26
BTIG Sticks to Their Buy Rating for Boston Scientific (BSX)
Barclays
$48
Hold
-3.73%
Downside
Initiated
10/07/26
Barclays Keeps Their Hold Rating on Boston Scientific (BSX)
Citi
$48
Hold
-3.73%
Downside
Assigned
10/05/26
Citi cuts Boston Scientific target, opens 'downside 90-day catalyst watch'Citi cuts Boston Scientific target, opens 'downside 90-day catalyst watch'
Bernstein Analyst forecast on BSX
Unknown Analyst
Bernstein
Not Ranked
Bernstein
$60→$54
Buy
8.30%
Upside
Assigned
10/02/26
Bernstein Keeps Their Buy Rating on Boston Scientific (BSX)
J.P. Morgan Analyst forecast on BSX
J.P. Morgan
J.P. Morgan
$56
Buy
12.31%
Upside
Reiterated
10/01/26
Analysts Offer Insights on Healthcare Companies: Boston Scientific (NYSE: BSX) and Artiva Biotherapeutics, Inc. (NASDAQ: ARTV)
RBC Capital Analyst forecast on BSX
RBC Capital
RBC Capital
$70
Buy
40.39%
Upside
Reiterated
10/01/26
Boston Scientific (BSX) Receives a Buy from RBC Capital
Wells Fargo Analyst forecast on BSX
Wells Fargo
Wells Fargo
$50→$48
Hold
-3.73%
Downside
Assigned
09/24/26
Boston Scientific price target lowered to $48 from $50 at Wells FargoBoston Scientific price target lowered to $48 from $50 at Wells Fargo
Oppenheimer Analyst forecast on BSX
Oppenheimer
Oppenheimer
$85→$65
Buy
30.37%
Upside
Assigned
09/21/26
Boston Scientific price target lowered to $65 from $85 at OppenheimerBoston Scientific price target lowered to $65 from $85 at Oppenheimer
Bank of America Securities Analyst forecast on BSX
Bank of America Securities
Bank of America Securities
$54
Buy
8.30%
Upside
Reiterated
09/20/26
Analysts Offer Insights on Healthcare Companies: Danaher (NYSE: DHR), Argenx Se (NASDAQ: ARGX) and Boston Scientific (NYSE: BSX)
TD Cowen
$56
Buy
12.31%
Upside
Reiterated
09/17/26
Analyst Maintains Buy on Boston Scientific, Viewing Cyberattack Impact as Short-Lived Despite Trimmed Near-Term Forecasts
Jefferies
$60
Buy
20.34%
Upside
Reiterated
09/11/26
Jefferies Sticks to Its Buy Rating for Boston Scientific (BSX)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
KNSAKiniksa Pharmaceuticals
OMCLOmnicell
AXGNAxoGen
ONCBeOne Medicines
AHCOAdaptHealth
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Boston Scientific

3 Months
Jayson BedfordRaymond James
Success Rate
34/53 ratings generated profit
64%
Average Return
+3.15%
Copying Jayson Bedford's trades and holding each position for 3 Months would result in 64.15% of your transactions generating a profit, with an average return of +3.15% per trade.
1 Year
Jayson BedfordRaymond James
Success Rate
39/53 ratings generated profit
74%
Average Return
+12.10%
Copying Jayson Bedford's trades and holding each position for 1 Year would result in 73.58% of your transactions generating a profit, with an average return of +12.10% per trade.
2 Years
Jayson BedfordRaymond James
Success Rate
41/53 ratings generated profit
77%
Average Return
+22.61%
Copying Jayson Bedford's trades and holding each position for 2 Years would result in 77.36% of your transactions generating a profit, with an average return of +22.61% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BSX Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
25
18
8
7
1
Buy
45
47
41
39
24
Hold
3
4
2
4
4
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
73
69
51
50
29
In the current month, BSX has received 25 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. BSX average Analyst price target in the past 3 months is 57.14.
Each month's total comprises the sum of three months' worth of ratings.

BSX Financial Forecast

BSX Earnings Forecast

Next quarter’s earnings estimate for BSX is $0.75 with a range of $0.58 to $0.84. The previous quarter’s EPS was $0.86. BSX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year BSX has Performed in-line its overall industry.
Next quarter’s earnings estimate for BSX is $0.75 with a range of $0.58 to $0.84. The previous quarter’s EPS was $0.86. BSX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year BSX has Performed in-line its overall industry.

BSX Sales Forecast

Next quarter’s sales forecast for BSX is $5.10B with a range of $4.71B to $5.30B. The previous quarter’s sales results were $5.44B. BSX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year BSX has Performed in-line its overall industry.
Next quarter’s sales forecast for BSX is $5.10B with a range of $4.71B to $5.30B. The previous quarter’s sales results were $5.44B. BSX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year BSX has Performed in-line its overall industry.

BSX Stock Forecast FAQ

What is BSX’s average 12-month price target, according to analysts?
Based on analyst ratings, Boston Scientific’s 12-month average price target is 57.14.
    What is BSX’s upside potential, based on the analysts’ average price target?
    Boston Scientific has 14.59% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is BSX a Buy, Sell or Hold?
          Boston Scientific has a consensus rating of Strong Buy which is based on 19 buy ratings, 4 hold ratings and 0 sell ratings.
            What is Boston Scientific’s price target?
            The average price target for Boston Scientific is 57.14. This is based on 23 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $70.00 ,the lowest forecast is $48.00. The average price target represents 14.59% Increase from the current price of $49.86.
              What do analysts say about Boston Scientific?
              Boston Scientific’s analyst rating consensus is a Strong Buy. This is based on the ratings of 23 Wall Streets Analysts.
                How can I buy shares of BSX?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.